Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07072832

Shelf Acetabuloplasty With 3D Printed Implants as a New Treatment for Symptomatic Adult Hip Dysplasia

Hip dysplasia is a common orthopedic condition, defined as an abnormality in the shape, size and orientation of the femoral head, acetabulum or both. The most frequent presentation of hip dysplasia is the maldevelopment of the acetabulum, resulting in insufficient superior coverage of the femoral head, defined as a lateral center-edge angle (Wiberg) of less than 20 degrees. Patients suffer from groin pain, an abnormal gait, decreased strength, and an increased rate of degenerative hip disease.

The possible treatments affecting the shape of the acetabulum once the patient reaches adolescence are all surgical. The PAO is regarded as the current gold standard in the treatment of symptomatic adult hip dysplasia. The 3-dimensional orientation of the acetabulum is changed with the use of 3 osteotomies around the acetabulum and a refixation in the obtained position. However, the PAO is a difficult operation and is associated with a large number of major complications (up to 37%), and the surgery is associated with a long rehabilitation period.

Hence, a strong unmet need exists for an effective but less invasive solution that enhances the quality of life of adult hip dysplasia patients. The treatment gap can be filled with a 3-dimensional (3D) shelf procedure. This custom-made implant (called the 3D-Shelf implant) was developed with the goal to be more predictable in terms of containment and fit than the old autologous shelf-acetabuloplasty, and less invasive and easier to perform than the PAO.

This study aims to study the safety and evaluate the early performance in terms of the clinical outcomes after implantation of the 3D-Shelf implant in patients with adult hip dysplasia, to show that the 3D-Shelf procedure is safe, has lower complication rates, and shows no inferiority in clinical outcomes compared to the current treatment of a peri-acetabular osteotomy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hip Dysplasia Hip Dislocation Hip Injuries Joint Diseases Joint Dislocations Musculoskeletal Diseases Wounds and Injuries

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Anna Ziekenhuis

Geldrop, 5664 BE, Netherlands

Location status: Recruiting

Location contact

Rintje Agricola, MD PhD

PRINCIPAL_INVESTIGATOR

Walter van der Weegen, PhD

CONTACT

[email protected]

+31402864278

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hip dysplasia based on AP x-ray with a LCEA of <25°
  • Groin pain and/or gait abnormalities, with no other explanatory hip pathology
  • Aged at least 18 years and maximal 45 years at time of surgery (indicated age for PAO(19))
  • Willing to comply with the study visit schedule during 12 month follow-up
  • Able and willing to provide informed consent

Exclusion criteria

  • Previous acetabular surgery >10yr of age
  • Signs of osteoarthritis on x-ray (Tonnis classification >1),
  • Body mass index of more than 35
  • Large labral tears visible on non-contrast MRI
  • Pre-consultation known titanium allergy
  • Pre-consultation known medical histories of diseases that per the investigator possibly affect the outcome: neuromuscular disease affecting the stability of the hip, diseases affecting bone ingrowth and fixation strength of the implant like rheumatoid arthritis and metabolic bone diseases, e.g. osteomalacie, osteoporosis, hyperparathyroidism, hypercalcemia.
  • Pre-consultation known pregnant women or women who are planning to become pregnant during the duration of the study.
  • Part of vulnerable population (e.g. Mentally disabled with cognitive impairment or mental disease)
  • Currently participating in another investigational clinical trial.
  • Unable to provide informed consent (e.g. insufficient language skills)

Treatment and study plan

3D-Shelf

Device

Treatment of hip dysplasia using novel 3D printed 3D-Shelf device.

Primary outcomes

  1. PROMs

    Time frame: from baseline (pre-surgery), 3 months, 6 months and 12 months.

    Performance and safety will be evaluated using patient-reported outcome measures, specifically the International Hip Outcome Tool (iHOT-33), which assesses health-related quality of life in young, active patients with hip disorders. Scores range from 0 to 100, with higher scores indicating better outcomes.

Secondary outcomes

  1. Implant position

    Time frame: 24 hours after surgery and 12 months after surgery

    Evaluation of the implant position using CT

  2. Recovery time

    Time frame: From 3 months, 6 months and 12 months

    Patient recovery will be evaluated through a combination of patient-reported and clinical outcomes. Patient-reported outcomes include the International Hip Outcome Tool (iHOT-33), which ranges from 0 to 100 with higher scores indicating better function and quality of life, and the EQ-5D. Clinical assessment will include evaluation of hip range of motion and return to normal function as judged by the investigator.

  3. Surgical risks

    Time frame: From surgery to end of follow-up (12 months)

    Evaluation of surgical risks will include monitoring and documentation of surgery-related adverse events and any deviations from the planned surgical procedure.

Sponsors and collaborators

Lead sponsor

Replasia BV

Industry

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jul 18, 2025
Registry last updated
Oct 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.